Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 10/20 | 0.63 |
| ▸ | GSTM2 | P28161 | 9/20 | 0.63 |
| ▸ | MYC | P01106 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | MAX | P61244 | 3/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13481780 | 0.85 | GSTP1 (0.58) | GSTP1GSTM2MYCMEN1KMT2A | |
| SCHEMBL7052057 | 0.84 | GSTM2 (0.66) | GSTP1GSTM2MYCMEN1KMT2A | |
| SCHEMBL13401376 | 0.78 | MYC (1.00) | GSTP1GSTM2MYCMEN1KMT2A | |
| SCHEMBL6834752 | 0.78 | GSTP1 (1.00) | GSTP1GSTM2MYCMEN1KMT2A | |
| SCHEMBL3047621 | 0.77 | MEN1 (0.60) | GSTP1GSTM2MYCMEN1KMT2A | |
| SCHEMBL2608494 | 0.75 | GSTP1 (0.61) | GSTP1GSTM2MYCMEN1KMT2A | |
| Bicarbonate SCHEMBL30336724 | 0.74 | IDO1 (0.52) | GSTP1GSTM2MYCMEN1KMT2A | |
| SCHEMBL21969702 | 0.74 | MEN1 (0.44) | GSTP1GSTM2MYCMEN1KMT2A | |
| SCHEMBL3192786 | 0.74 | IDO1 (0.57) | GSTP1GSTM2MYCMEN1KMT2A | |
| SCHEMBL41754 | 0.74 | IDO1 (0.58) | GSTP1GSTM2MYCMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470861-B2 | Mitochondria-targeted antioxidant prodrugs and methods of use | UNIVERSITY OF ROCHESTER (US) | 2013-06-25 | — | — | US | disclosed |
| US-20100168198-A1 | Mitochondria-targeted antioxidant prodrugs and methods of use | UNIVERSITY OF ROCHESTER | 2010-07-01 | — | — | US | disclosed |
| US-7655689-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20090306125-A1 | Mitochondria-Targeted Antioxidant Prodrugs and Methods of Use | UNIVERSITY OF ROCHESTER | 2009-12-10 | — | — | US | disclosed |
| US-7517904-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7470797-B2 | Fused heterocyclic imido and amido compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470797-B2 | Fused heterocyclic imido and amido compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1954322-A2 | MITOCHONDRIA-TARGETED ANTIOXIDANT PRODRUGS AND METHODS OF USE | University of Rochester (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007062343-A2 | MITOCHONDRIA-TARGETED ANTIOXIDANT PRODRUGS AND METHODS OF USE | UNIVERSITY OF ROCHESTER (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306125-A1 | Mitochondria-Targeted Antioxidant Prodrugs and Methods of Use | TXNRD2, HADHA, PRDX5 | GSTP1 230/4885GSTM2 231/4885MYC 3672/4885 |
| US-20100168198-A1 | Mitochondria-targeted antioxidant prodrugs and methods of use | TXNRD2, HADHA, PRDX5 | GSTP1 230/4885GSTM2 231/4885MYC 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.